Home > Insider Trading > Filing (0000914475-25-000069)

Filing Details

Accession Number:: 0000914475-25-000069
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-02-14 18:42:06
Reporting Period:: 2025-02-12

Filing Date:: 2025-02-14
Accepted Time:: 2025-02-14 18:42:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
914475	Neurocrine Biosciences Inc	NBIX	Biological Products, (No Disgnostic Substances) (2836)	330525145

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1727606	Eiry Roberts	12780 El Camino Real San Diego CA 92130	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-02-13	2,113	$0.00	35,366	No	4	M	Direct
Common Stock	Disposition	2025-02-13	1,114	$116.90	34,252	No	4	S	Direct
Common Stock	Acquisiton	2025-02-13	1,120	$0.00	35,372	No	4	M	Direct
Common Stock	Disposition	2025-02-13	604	$116.74	34,768	No	4	S	Direct
Common Stock	Acquisiton	2025-02-13	1,372	$0.00	36,140	No	4	M	Direct
Common Stock	Disposition	2025-02-14	500	$115.04	35,640	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option	Acquisiton	2025-02-12	43,261	$0.00	43,261	$117.18
Common Stock	Restricted Stock Unit	Acquisiton	2025-02-12	8,108	$0.00	8,108	$0.00
Common Stock	Restricted Stock Unit	Disposition	2025-02-13	2,113	$0.00	2,113	$0.00
Common Stock	Restricted Stock Unit	Disposition	2025-02-13	1,120	$0.00	1,120	$0.00
Common Stock	Restricted Stock Unit	Disposition	2025-02-13	1,372	$0.00	1,372	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
43,261	2035-02-12	No	4	A	Direct
8,108		No	4	A	Direct
4,227		No	4	M	Direct
3,363		No	4	M	Direct
4,115		No	4	M	Direct

Footnotes

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.24 to $117.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $118.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $114.76 to $115.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
34,455 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029.
This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, and will vest as to 2,113 shares on February 13, 2026, and 2,114 shares on February 13, 2027, subject to the terms and conditions of the award.
This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, and will vest as to 1,121 shares on February 13, 2026, 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award.
This RSU was granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, and will vest as to 1,372 shares on February 13, 2026, 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award.